Loading viewer...
investor_presentation
Format: PDF investor_presentation
1| Maximus: Q1 FY22 Earnings Presentation David Mutryn Chief Financial OfficerFiscal 2022 First QuarterEarnings Call February 3, 2022
1| Maximus: Q1 FY22 Earnings Presentation
Chief Financial OfficerFiscal 2022
First QuarterEarnings Call
2| Maximus: Q1 FY22 Earnings PresentationThese slides should be read in conjunction with the Company’s most recent quarterly earnings press release, along with listening to or reading a transcript of the comments of
Company management from our most recent quarterly earnings conference call.
This document may contain non- GAAP financial information. Management uses this information in its internal analysis of results and believes that this information may be informative
to investors in gauging the quality of our financial performance, identifying trends in our results, and providing meaningful period -to-period comparisons. These measures should be
used in conjunction with, rather than instead of, their comparable GAAP measures. For a reconciliation of non- GAAP measures to t he comparable GAAP measures presented in this
document, see the Company’s most recent quarterly earnings press release.In this presentation, we use terms such as “normalized organic growth.” We calculate this number by removing the effects of t he U.S. Census contract, the estimated revenues from
COVID -19 response work, the benefit from our acquisitions and the period- over-period currency effects from our revenue. We believe normalized organic growth allows our investors
to understand the effect on our revenue and revenue growth of various key drivers whose effects will vary from year to year. It should be used to complement analysis of our revenue
Included in this presentation are forward- looking statements within the meaning of the safe harbor provisions of the United Stat es Private Securities Litigation Reform Act of 1995.
Forward -looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “opportunity,” “c ould,” “potential,” “believe,” “project,” “estimate,” “expect,”
“strategy,” “future,” “likely,” “may,” “should,” “will,” and similar references to future periods.
Forward -looking statements that are not historical facts, including statements about our confidence, strategies and initiatives and our expectations about revenues, results of
operations, profitability, liquidity, market demand or the impact of the pandemic are forward- looking statements that involve ri sks and uncertainties such as those related to the impact
of the pandemic and our recently -completed acquisitions.
These risks could cause the Company’s actual results to differ materially from those indicated by such forward- looking statement s. A summary of risk factors can be found in Item 1A,
"Risk Factors" in our Annual Report on Form 10- K for the year ended September 30, 2021, which was filed with the Securities and Exchange Commission (SEC) on November 18,
Any forward- looking statement made by us in this report is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no
Preview truncated — download the full document for the complete content.
investor_presentation
17 Pages
investor_presentation
32 Pages
Criteo
Zentalis Pharmaceuticals Investor Presentation — November 2022
investor_presentationinvestor_presentation
56 Pages
Zentalis Pharmaceuticals, Inc.